Mixed response to osimertinib and the beneficial effects of additional local therapy

BACKGROUND: Although non‐small cell lung cancers (NSCLCs) harboring EGFR mutations initially respond well to EGFR‐tyrosine kinase inhibitors (TKIs), they typically progress after approximately one year. The EGFR T790M mutation is the most common resistance mechanism. NSCLCs with T790M respond well t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinno, Yuki, Goto, Yasushi, Sato, Jun, Morita, Ryo, Matsumoto, Yuji, Murakami, Shuji, Kanda, Shintaro, Horinouchi, Hidehito, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449255/
https://www.ncbi.nlm.nih.gov/pubmed/30735003
http://dx.doi.org/10.1111/1759-7714.12991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449255/
https://www.ncbi.nlm.nih.gov/pubmed/30735003
http://dx.doi.org/10.1111/1759-7714.12991

Ejemplares similares